ストックスクリーナーアプリを入手
12.49
3.65%
0.44
アフターアワーズ：
12.33
-0.16
-1.28%
Bausch Lomb Corp (BLCO) 最新ニュース
Is Bausch + Lomb (BLCO) the Most Undervalued Canadian Stock to Buy According to Wall Street Analysts? - Yahoo Finance
Fitch upgrades Bausch + Lomb rating, maintains evolving watch - Investing.com
Fitch upgrades Bausch + Lomb rating, maintains evolving watch By Investing.com - Investing.com Canada
Fitch Upgrades Bausch + Lomb, Bausch Health But Keeps Both Junk - Bloomberg
Bausch & Lomb Corp (BLCO) Shares Down 3.1% on Apr 15 - GuruFocus
Bausch & Lomb Agrees to End Vitamin-Patent Suit Ahead of Trial - Bloomberg Law News
Bausch + Lomb (BLCO) Moves 13.9% Higher: Will This Strength Last? - Yahoo
Ophthalmic Devices Market Set to Attain Valuation of US$ 83.33 Billion By 2033 | Astute Analytica - GlobeNewswire Inc.
Q4 Earnings Roundup: Bausch + Lomb (NYSE:BLCO) And The Rest Of The Medical Devices & SuppliesSpecialty Segment - Yahoo Finance
Bausch + Lomb Gears Up For Q1 2025 Results Announcement - Finimize
RBC Capital cuts Bausch & Lomb price target to $17, maintains Outperform - Investing.com
Stifel cuts Bausch & Lomb stock target to $15, maintains hold - Investing.com UK
Lawyers focus on Bausch + Lomb recall investigation | 2025-03-31 | Investing News - Stockhouse
Bausch & Lomb Patents’ Validity Should Go to Trial, Judge Says - Bloomberg Law News
WF downgrades Bausch + Lomb on enVista recall giving a near-term uncertainty - Baystreet.ca
Wells Fargo cuts Bausch & Lomb stock rating, lowers target to $15 - Investing.com UK
Bausch + Lomb recalls some of its implantable eye lenses - Reuters
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb shares fall on voluntary recall By Investing.com - Investing.com India
Bausch + Lomb to Announce Q1 2025 Financial Results - TipRanks
Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30 - Yahoo Finance
Bausch & Lomb Says Amcor Must Pay For Botched Bottles - Law360
Bausch + Lomb credit rating upgraded to ’B’ at S&P, parent company outlook developing - Investing.com India
Jury Should Hear Bausch & Lomb Vitamin-Patent Claims, Judge Says - Bloomberg Law News
Stocks In Play: Bausch + Lomb Corporation - Barchart
Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States - BioSpace
Contact Lenses Market Forecast Report and Company Analysis 2025-2033 Featuring Bausch & Lomb, Alcon, Carl Zeiss Meditec, The Cooper Companies, Hoya, EssilorLuxottica, Menicon, and Seed - Yahoo Finance
U.S. Contact Lenses Market Size and Share Analysis 2025-2033, Featuring Bausch & Lomb, Alcon, Carl Zeiss Meditec, The Cooper Companies, Hoya Corporation & More - Yahoo Finance
Judge Advises Affirming Bausch & Lomb Vitamin Patents' Validity - Bloomberg Law News
Bausch + Lomb's SWOT analysis: eye health stock sees growth amid challenges - Investing.com
Morgan Stanley cuts Bausch & Lomb stock target to $18 from $19 - Investing.com
Bausch + Lomb Co. (NYSE:BLCO) Receives Average Rating of “Hold” from Analysts - Defense World
Bank of America Lowers Bausch + Lomb (NYSE:BLCO) Price Target to $17.00 - Defense World
Bausch & Lomb stock target cut to $20 at H.C. Wainwright - Investing.com UK
Bausch + Lomb Corporation (NYSE:BLCO) Q4 2024 Earnings Call Transcript - Insider Monkey
Bausch & Lomb Begins to Reap Fruits of Innovation; Broad-Based Growth Fuels Our Long-Term Outlook - Morningstar
Bausch + Lomb Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance - BioSpace
Bausch + Lomb Corp. Announces FY25 Revenue Within View - Nasdaq
Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results - TradingView
Bausch + Lomb Posts Q4 Revenue of US$1.28 Billion -February 19, 2025 at 06:59 am EST - Marketscreener.com
Bausch + Lomb shares surge over 4% on earnings beat and strong outlook - Investing.com
Short Interest in Bausch + Lomb Co. (NYSE:BLCO) Increases By 37.3% - MarketBeat
Bausch + Lomb (BLCO) Reports Earnings Tomorrow: What To Expect - Yahoo Finance
Unlocking Q4 Potential of Bausch + Lomb (BLCO): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Bausch + Lomb Sinks After Disclosing It Won’t Go Private Now - Bloomberg
Contact lens maker Bausch + Lomb rules out going private at this time - Reuters
Bausch + Lomb sinks after disclosing it won’t go private now - The Malaysian Reserve
Contact lens maker Bausch + Lomb rules out take-private deal - Yahoo Canada Finance
Bausch + Lomb Provides Update on Potential Sale - Business Wire
Brokerages Set Bausch + Lomb Co. (NYSE:BLCO) Target Price at $20.25 - MarketBeat
Stifel Nicolaus Issues Pessimistic Forecast for Bausch + Lomb (NYSE:BLCO) Stock Price - Defense World
1.60%
大文字化:
|
ボリューム (24 時間):